1. Home
  2. RIGL vs FSBW Comparison

RIGL vs FSBW Comparison

Compare RIGL & FSBW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RIGL
  • FSBW
  • Stock Information
  • Founded
  • RIGL 1996
  • FSBW 1936
  • Country
  • RIGL United States
  • FSBW United States
  • Employees
  • RIGL N/A
  • FSBW N/A
  • Industry
  • RIGL Biotechnology: Pharmaceutical Preparations
  • FSBW Banks
  • Sector
  • RIGL Health Care
  • FSBW Finance
  • Exchange
  • RIGL Nasdaq
  • FSBW Nasdaq
  • Market Cap
  • RIGL 366.5M
  • FSBW 318.4M
  • IPO Year
  • RIGL 2000
  • FSBW 2012
  • Fundamental
  • Price
  • RIGL $17.17
  • FSBW $37.99
  • Analyst Decision
  • RIGL Buy
  • FSBW Hold
  • Analyst Count
  • RIGL 5
  • FSBW 1
  • Target Price
  • RIGL $36.80
  • FSBW $44.00
  • AVG Volume (30 Days)
  • RIGL 253.6K
  • FSBW 13.3K
  • Earning Date
  • RIGL 03-04-2025
  • FSBW 04-23-2025
  • Dividend Yield
  • RIGL N/A
  • FSBW 2.84%
  • EPS Growth
  • RIGL N/A
  • FSBW N/A
  • EPS
  • RIGL 0.99
  • FSBW 4.36
  • Revenue
  • RIGL $179,278,000.00
  • FSBW $139,150,000.00
  • Revenue This Year
  • RIGL $14.19
  • FSBW $9.22
  • Revenue Next Year
  • RIGL $13.10
  • FSBW $6.31
  • P/E Ratio
  • RIGL $17.17
  • FSBW $8.72
  • Revenue Growth
  • RIGL 54.71
  • FSBW 0.09
  • 52 Week Low
  • RIGL $7.48
  • FSBW $30.64
  • 52 Week High
  • RIGL $29.82
  • FSBW $49.15
  • Technical
  • Relative Strength Index (RSI)
  • RIGL 34.02
  • FSBW 49.99
  • Support Level
  • RIGL $17.01
  • FSBW $37.27
  • Resistance Level
  • RIGL $19.97
  • FSBW $39.40
  • Average True Range (ATR)
  • RIGL 1.01
  • FSBW 0.97
  • MACD
  • RIGL -0.29
  • FSBW 0.25
  • Stochastic Oscillator
  • RIGL 10.65
  • FSBW 64.72

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

About FSBW FS Bancorp Inc.

FS Bancorp Inc is the holding company of 1st Security Bank, a diversified lender with a focus on the origination of commercial real estate, one-to-four-family, and home equity loans, consumer loans, including a variety of indirect home improvement (fixture secured loans), and marine loans, and commercial business loans. The company has two operating segments; The commercial and consumer banking segment provides diversified financial products and services to its commercial and consumer customers through Bank branches, automated teller machines, online banking platforms, mobile banking apps, and telephone banking, and The home lending segment originates one-to-four-family residential mortgage loans for sale in the secondary markets as well as loans held for investment.

Share on Social Networks: